Alliance Global Partners analyst James Molloy lowered the firm’s price target on Ocuphire Pharma (OCUP) to $20 from $24 and keeps a Buy rating on the shares following the Q4 report. The FDA approved Ryzumvi for the treatment of harmacologically-induced mydriasis in September 2023, and with Ocuphire ‘s partnership with Viatris (VTRS), a launch of Ryzumvi is planned for the first half of 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUP:
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
- Ocuphire Pharma expects cash to fund operations into mid-2025
- Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)
- OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocuphire Pharma to Present in the BIO CEO & Investor Conference